This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yagci, D.
Right arrow Articles by Memikoglu, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yagci, D.
Right arrow Articles by Memikoglu, O.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2009, p. 1287-1289, Vol. 53, No. 3
0066-4804/09/$08.00+0     doi:10.1128/AAC.01228-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Prevalence and Risk Factors for Selection of Quinolone-Resistant Escherichia coli Strains in Fecal Flora of Patients Receiving Quinolone Therapy{triangledown}

D. Yagci, F. Yoruk,* A. Azap, and O. Memikoglu

Ankara University, School of Medicine, Department of Clinical Microbiology and Infectious Diseases, Ankara, Turkey

Received 16 September 2008/ Returned for modification 29 October 2008/ Accepted 1 December 2008

Patients taking quinolones as inpatients (n = 55) or outpatients (n = 40) and newly hospitalized patients who were not on quinolone therapy (n = 41) were assessed for fecal carriage of quinolone-resistant Escherichia coli (QREC) strains before and after therapy/hospitalization. Fluoroquinolone use in the previous 6 months was found to be a risk factor for QREC carriage before therapy/hospitalization. The prevalence of QREC strains in fecal flora increased steadily with the duration of quinolone therapy.

* Corresponding author. Mailing address: Ankara Üniversitesi Tip Fakültesi, Klinik Mikrobiyoloji ve Infeksiyon Hastaliklari, Anabilim Dali, Akademik Yerleske M-01, 06100 Samanpazari/Ankara, Turkey. Phone: 90 312 5083288. Fax: 90 312 3240328. E-mail: fugenyoruk{at}gmail.com

{triangledown} Published ahead of print on 8 December 2008.

Antimicrobial Agents and Chemotherapy, March 2009, p. 1287-1289, Vol. 53, No. 3
0066-4804/09/$08.00+0     doi:10.1128/AAC.01228-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»